Subfoveal choroidal melanoma: Pretreatment characteristics and response to plaque radiation therapy

Archives of Ophthalmology

Volumn 129, Issue 7, 2011, Pages 892-898

  Newman, Hadas ^a,b   Chin, Kimberly J ^a   Finger, Paul T ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PALLADIUM 103; RANIBIZUMAB;

ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CHOROID MELANOMA; CLINICAL ARTICLE; CRYOTHERAPY; ENUCLEATION; FOLLOW UP; HUMAN; LASER COAGULATION; LOW LEVEL LASER THERAPY; MEDICAL RECORD REVIEW; METASTASIS; PRIORITY JOURNAL; RADIATION CATARACT; RADIATION INJURY; RETINA DETACHMENT; RETINA FOVEA; RETINA MACULOPATHY; RETINOPATHY; SUBRETINAL FLUID; VISUAL ACUITY; VITRECTOMY;

BRACHYTHERAPY; CHOROID NEOPLASMS; FOLLOW-UP STUDIES; FOVEA CENTRALIS; HUMANS; MELANOMA; NEOPLASM STAGING; PALLADIUM; RADIATION INJURIES; RADIOISOTOPES; RADIOTHERAPY DOSAGE; RETINA; VISUAL ACUITY;

EID: 79960198693     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.161     Document Type: Article

References (32)

1. Finger PT, Chin KJ, Duvall G; Palladium-103 for Choroidal Melanoma Study Group. Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. Ophthalmology. 2009;116(4):790-796, 796.e1. doi:10.1016/j.ophtha.2008.12.027.
2. Collaborative Ocular Melanoma Study Group; Boldt HC, Byrne SF, Gilson MM, et al. Baseline echographic characteristics of tumors in eyes of patients enrolled in the Collaborative Ocular Melanoma Study: COMS report No. 29. Ophthalmology. 2008;115(8):1390-1397, 1397.e1-1397.e2. doi:10.1016/j.ophtha. 2007.12.015.
3. Finger PT. Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2000;84(9):1068-1070.
4. Melia BM, Abramson DH, Albert DM, et al; Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma, I: visual acuity after 3 years: COMS report No. 16. Ophthalmology. 2001;108(2):348-366. (Pubitemid 32115968)
5. Finger PT, Chin KJ, Yu GP; Palladium-103 for Choroidal Melanoma Study Group. Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma. Am J Ophthalmol. 2010;149(4):608-615.
6. Jampol LM, Moy CS, Murray TG, et al; Collaborative Ocular Melanoma Study Group (COMS Group). The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, IV: local treatment failure and enucleation in the first 5 years after brachytherapy: COMS report No. 19. Ophthalmology. 2002;109(12):2197-2206. (Pubitemid 35417099)
7. Finger PT, Berson A, Ng T, Szechter A. Palladium-103 plaque radiotherapy for choroidal melanoma: an 11-year study. Int J Radiat Oncol Biol Phys. 2002; 54(5):1438-1445. (Pubitemid 35380045)
8. AJCC Ophthalmic Oncology Task Force. Malignant melanoma of the uvea. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, eds. The AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009:547-559.
9. Collaborative Ocular Melanoma Study Group. Design and methods of a clinical trial for a rare condition: the Collaborative Ocular Melanoma Study: COMS report No. 3. Control Clin Trials. 1993;14(5):362-391. doi:10.1016/0197- 2456(93)90052-F.
10. Finger PT, Kurli M. Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2005;89(6):730-738. (Pubitemid 40780582)
11. Astrahan MA, Szechter A, Finger PT. Design and dosimetric considerations of a modified COMS plaque: the reusable "seed-guide" insert. Med Phys. 2005; 32(8):2706-2716.
12. Earle J, Kline RW, Robertson DM. Selection of iodine 125 for the Collaborative Ocular Melanoma Study. Arch Ophthalmol. 1987;105(6):763-764. (Pubitemid 17082534)
13. Ray SK, Bhatnagar R, Hartsell WF, Desai GR; American Association of Physicists in Medicine. Review of eye plaque dosimetry based on AAPM Task Group 43 recommendations. Int J Radiat Oncol Biol Phys. 1998;41(3):701-706. (Pubitemid 28275104)
14. Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT; American Brachytherapy Society. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys. 2003;56(2):544-555. (Pubitemid 36542915)
15. Beyer D, Nath R, Butler W, et al; Clinical Research Committee of the American Brachytherapy Society. American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for 103palladium brachytherapy. Int J Radiat Oncol Biol Phys. 2000;47(2):273-275. (Pubitemid 30236365)
16. Vikram B. American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for palladium-103 brachytherapy: in regard to Beyer et al. IJROBP. 2000;47:273-275 [letter]. Int J Radiat Oncol Biol Phys. 2001;49(3):898-899.
17. Finger PT, Romero JM, Rosen RB, Iezzi R, Emery R, Berson A. Three-dimensional ultrasonography of choroidal melanoma: localization of radioactive eye plaques. Arch Ophthalmol. 1998;116(3):305-312.
18. Harbour JW, Murray TG, Byrne SF, et al. Intraoperative echographic localization of iodine 125 episcleral radioactive plaques for posterior uveal melanoma. Retina. 1996;16(2):129-134. (Pubitemid 26120229)
19. Finger PT, Chin KJ. Intravitreous ranibizumab (Lucentis) for radiationmaculopathy. Arch Ophthalmol. 2010;128(2):249-252.
20. Finger PT. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys. 2008;70(4):974-977. (Pubitemid 351296131)
21. Finger PT, Chin K. Anti-vascular endothelial growth factor bevacizumab (Avastin) for radiation retinopathy. Arch Ophthalmol. 2007;125(6):751-756. (Pubitemid 46919735)
22. Yanoff M, Fine BS. Ocular Pathology. 4th ed. London, England: Mosby-Wolfe; 1996.
23. Kivelä T, Eskelin S, Mäkitie T, Summanen P. Exudative retinal detachment from malignant uveal melanoma: predictors and prognostic significance. Invest Ophthalmol Vis Sci. 2001;42(9):2085-2093. (Pubitemid 32726043)
24. Gass JD. Observation of suspected choroidal and ciliary body melanomas for evidence of growth prior to enucleation. Ophthalmology. 1980;87(6):523-528. (Pubitemid 10066559)
25. Erie JC, Robertson DM, Mieler WF. Presumed small choroidal melanomas with serous macular detachments with and without surface laser photocoagulation treatment. Am J Ophthalmol. 1990;109(3):259-264. (Pubitemid 20078943)
26. Butler P, Char DH, Zarbin M, Kroll S. Natural history of indeterminate pigmented choroidal tumors. Ophthalmology. 1994;101(4):710-717. (Pubitemid 24113232)
27. Augsburger JJ, Schroeder RP, Territo C, Gamel JW, Shields JA. Clinical parameters predictive of enlargement of melanocytic choroidal lesions. Br J Ophthalmol. 1989;73(11):911-917. (Pubitemid 20004006)
28. Egan KM, Gragoudas ES, Seddon JM, et al. The risk of enucleation after proton beam irradiation of uveal melanoma. Ophthalmology. 1989;96(9):1377-1383. (Pubitemid 19231768)
29. Foss AJ, Whelehan I, Hungerford JL, et al. Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma. Br J Ophthalmol. 1997;81(9):748-754. (Pubitemid 27453581)
30. Summanen P, Immonen I, Kivelä T, Tommila P, Heikkonen J, Tarkkanen A. Visual outcome of eyes with malignant melanoma of the uvea after ruthenium plaque radiotherapy. Ophthalmic Surg Lasers. 1995;26(5):449-460.
31. Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Visual acuity after ruthenium106 brachytherapy of choroidal melanomas. Int J Radiat Oncol Biol Phys. 2005;63(2):392-400. (Pubitemid 41317155)
32. Finger PT, Chin KJ, Yu GP, Patel NS; Palladium-103 for Choroidal Melanoma Study Group. Risk factors for cataract after palladium-103 ophthalmic plaque radiation therapy [published online July 7, 2010]. Int J Radiat Oncol Biol Phys. doi: 10.1016/j.ijrobp.2010.02.051.